Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Dodd

Showing results (331-340 of 339) with videos related to

Pageof 34
Sort By:
You have reached the last page of results.This site can display upto 339 results.
Bioorganic & Medicinal Chemistry Letters|June 28, 2011
Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitorsAlaric J Dyckman, Tianle Li, Sidney Pitt, et al.
Bioorganic & Medicinal Chemistry Letters|May 10, 2006
Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitorsJagabandhu Das, Joseph A Furch, Chunjian Liu, et al.
Bioorganic & Medicinal Chemistry Letters|June 11, 2013
The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding modeStephen T Wrobleski, Shuqun Lin, T G Murali Dhar, et al.
Implementation Science : IS|March 24, 2026
Ready to screen implementation trial protocol: a cluster randomized implementation trial comparing a bundled implementation strategy versus a simple implementation strategy to improve intention to screen in the Australian National Lung Cancer Screening ProgramDzenana Kartal, Christine Paul, Georgia Bartlett, et al.
Bioorganic & Medicinal Chemistry Letters|October 25, 2011
Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066)Scott H Watterson, Charles M Langevine, Katy Van Kirk, et al.
Journal of Medicinal Chemistry|September 12, 2015
Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase InhibitorChunjian Liu, James Lin, John Hynes, et al.
Biochemistry|August 25, 2004
Selective Itk inhibitors block T-cell activation and murine lung inflammationTai-An Lin, Kim W McIntyre, Jagabandhu Das, et al.
Journal of Medicinal Chemistry|March 10, 2009
Novel tricyclic inhibitors of IkappaB kinaseJames Kempson, Steven H Spergel, Junqing Guo, et al.
Journal of Medicinal Chemistry|September 1, 2010
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseasesChunjian Liu, James Lin, Stephen T Wrobleski, et al.
Pageof 34

Showing results (331-340 of 339) with videos related to

Sort By:
Pageof 34
You have reached the last page of results.This site can display upto 339 results.
Bioorganic & Medicinal Chemistry Letters|June 28, 2011
Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitorsAlaric J Dyckman, Tianle Li, Sidney Pitt, et al.
Bioorganic & Medicinal Chemistry Letters|May 10, 2006
Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitorsJagabandhu Das, Joseph A Furch, Chunjian Liu, et al.
Bioorganic & Medicinal Chemistry Letters|June 11, 2013
The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding modeStephen T Wrobleski, Shuqun Lin, T G Murali Dhar, et al.
Implementation Science : IS|March 24, 2026
Ready to screen implementation trial protocol: a cluster randomized implementation trial comparing a bundled implementation strategy versus a simple implementation strategy to improve intention to screen in the Australian National Lung Cancer Screening ProgramDzenana Kartal, Christine Paul, Georgia Bartlett, et al.
Bioorganic & Medicinal Chemistry Letters|October 25, 2011
Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066)Scott H Watterson, Charles M Langevine, Katy Van Kirk, et al.
Journal of Medicinal Chemistry|September 12, 2015
Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase InhibitorChunjian Liu, James Lin, John Hynes, et al.
Biochemistry|August 25, 2004
Selective Itk inhibitors block T-cell activation and murine lung inflammationTai-An Lin, Kim W McIntyre, Jagabandhu Das, et al.
Journal of Medicinal Chemistry|March 10, 2009
Novel tricyclic inhibitors of IkappaB kinaseJames Kempson, Steven H Spergel, Junqing Guo, et al.
Journal of Medicinal Chemistry|September 1, 2010
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseasesChunjian Liu, James Lin, Stephen T Wrobleski, et al.
Pageof 34